Actinogen Medical Limited has received an AU$ 9.0 million rebate for its research and development tax incentives

Actinogen Medical Limited (ASX: ACW) announced it had secured a significant research and development tax incentive rebate of AU$ 9,034,351 from the Australian Tax Office for the 2024 financial year. This R&D tax incentive is a vital Australian federal government program that rewards companies with cash refunds for eligible research and development expenditures.

This critical funding source strengthens its financial position and ensures it has the necessary cash runway to mid-2026 when combined with its current resources. This will enable it to fully enroll 220 participants in its critical Alzheimer’s phase 2b/3 clinical trial, bringing it closer to making a meaningful impact in this area of research.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com